These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11736977)

  • 1. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer.
    George ML; Dzik-Jurasz AS; Padhani AR; Brown G; Tait DM; Eccles SA; Swift RI
    Br J Surg; 2001 Dec; 88(12):1628-36. PubMed ID: 11736977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.
    McDonnell CO; Harmey JH; Bouchier-Hayes DJ; Walsh TN
    Br J Surg; 2001 Aug; 88(8):1105-9. PubMed ID: 11488797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
    Atkin G; Taylor NJ; Daley FM; Stirling JJ; Richman P; Glynne-Jones R; d'Arcy JA; Collins DJ; Padhani AR
    Br J Surg; 2006 Aug; 93(8):992-1000. PubMed ID: 16673354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.
    Minagawa N; Nakayama Y; Hirata K; Onitsuka K; Inoue Y; Nagata N; Itoh H
    Anticancer Res; 2002; 22(5):2957-63. PubMed ID: 12530025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of postoperative serum vascular endothelial growth factor (VEGF)--can it be used to predict curative resections in colorectal cancer?
    Kumar H; Heer K; Duthie GS; Monson JR
    Anticancer Res; 2002; 22(6B):3717-22. PubMed ID: 12552982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
    Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST
    Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
    Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
    Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
    Nakayama Y; Sako T; Shibao K; Okazaki K; Rempo N; Onitsuka K; Minagawa N; Akahane K; Nagashima N; Nagata N; Itoh H
    Anticancer Res; 2002; 22(4):2437-42. PubMed ID: 12174940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
    Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
    Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
    Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
    J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A; Janson ET; Eriksson B; Larsson A
    Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.
    Van den Eynden GG; Van der Auwera I; Van Laere SJ; Trinh XB; Colpaert CG; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
    J Pathol; 2007 Sep; 213(1):56-64. PubMed ID: 17674348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.
    Dhar DK; Ono T; Yamanoi A; Soda Y; Yamaguchi E; Rahman MA; Kohno H; Nagasue N
    Cancer; 2002 Nov; 95(10):2188-95. PubMed ID: 12412173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
    Oliver VK; Patton AM; Desai S; Lorang D; Libutti SK; Kohn EC
    J Cell Physiol; 2003 Oct; 197(1):139-48. PubMed ID: 12942550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
    Peng XP; Li JD; Li MD; Ye XM; Yan WC
    Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.